Table 3.
Clinical Outcomes at 12-month follow-up.
N = 259 | |
---|---|
MACE at 12 months, n, % | 10 (4) |
CVS mortality, n, % | 4 (1.5) |
TLR, n, % | 4 (1.5) |
MI, n, % | 5 (2) |
Stent thrombosis, n, % | 4 (1.5) |
MACE: major adverse cardiac event, CVS: cardiovascular, TLR: target lesion revascularization, MI: myocardial infarction.